Lactobacillus delbrueckii ssp. bulgaricus strain and compositions

• US 7,901,925 B2
• Filed: 06/23/2006
• Issued: 03/08/2011
• Est. Priority Date: 06/23/2006
• Status: Active Grant

• Current Assignee: LacPro Industries LLC
• Original Assignee: LacPro Industries LLC
• Inventors: Bojrab, Gregory G.
• Primary Examiner(s): Marx; Irene
• Application Number:
  US11/473,654
• Publication Number:
  US 20070298019A1
• Time in Patent Office: 1,719 Days
• Field of Search: None
• US Class Current: 435/252.9
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: C12N 1/20 Bacteria; Culture media therefor
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12R 2001/225 Lactobacillus

Abstract

A novel strain of Lactobacillus delbrueckii, ssp. bulgaricus, including probiotic compositions comprising the bacteria, and methods for using the bacteria and/or the compositions for treatments of diseased states and boosting immune response.

Claims

1. An isolated culture of the bacterial strain Lactobacillus delbrueckii, ssp. bulgaricus having accession number NRRL B-30892.

2. An isolated culture of a bacterial strain of the genus Lactobacillus, having all of the identifying characteristics of the Lactobacillus bacteria deposited in the Agricultural Research Service Patent Culture Collection and given the NRRL Accession No. B-30892.

3. A probiotic composition comprising Lactobacillus delbrueckii, ssp. bulgaricus in a carbohydrate-containing medium, the Lactobacillus delbrueckii, ssp. bulgaricus having accession number NRRL B-30892, whereby the probiotic composition contains a therapeutically effective dose of Lactobacillus delbrueckii, ssp. bulgaricus having accession number NRRL B-30892 to eliminate alleviate the symptoms of Clostridium difficile associated disease.

4. The probiotic composition of claim 3, wherein the therapeutically effective dose is at least about 1.3×

10e10 colony forming units in 24 ounces or less of the carbohydrate-containing medium.

5. The probiotic composition of claim 4, wherein the carbohydrate-containing medium is a milk-based product.

6. The probiotic composition of claim 5, wherein the milk-based product is a vegetable milk or milk derived from an animal.

7. The probiotic composition of claim 4 wherein the therapeutically effective dose of Lactobacillus delbrueckii, ssp. bulgaricus is at least about 1.4×

10e10 colony forming units.

8. The probiotic composition of claim 7, wherein the therapeutic dose of Lactobacillus delbrueckii, ssp. bulgaricus is at least about 3×

10e10 colony forming units.

9. The probiotic composition of claim 7, wherein the therapeutic dose of Lactobacillus delbrueckii, ssp. bulgaricus is in about 10 ounces or less of the composition.

10. The probiotic composition of claim 7, wherein the therapeutically effective dose effectively alleviates the symptoms of a diseased state selected from the group consisting of Crohn'"'"'s disease, ulcerative colitis, irritable bowel syndrome, inflammatory bowel disease, diarrhea, hyperlipidemia, hypovitaminosis, antibiotic-associated diarrhea, and Clostridium difficile associated disease.